Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib
Authors
Keywords
Hepatocellular carcinoma, Sorafenib, Metapristone, SDF-1/CXCR4, PLGA-PEG, Combination therapy
Journal
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
Volume 38, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-05-31
DOI
10.1186/s13046-019-1216-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond
- (2018) Jean-Luc Raoul et al. CANCER TREATMENT REVIEWS
- Combined treatment with sorafenib and silibinin synergistically targets both HCC cells and cancer stem cells by enhanced inhibition of the phosphorylation of STAT3/ERK/AKT
- (2018) Jie Mao et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development
- (2018) Yun-Chieh Sung et al. Theranostics
- CXCR4 targeted dendrimer for anti-cancer drug delivery and breast cancer cell migration inhibition
- (2017) Chuda Chittasupho et al. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
- Abortifacient metapristone (RU486 derivative) interrupts CXCL12/CXCR4 axis for ovarian metastatic chemoprevention
- (2017) Ning Zheng et al. MOLECULAR CARCINOGENESIS
- Synergistic chemotherapeutic effect of sorafenib-loaded pullulan-Dox conjugate nanoparticles against murine breast carcinoma
- (2017) Junhui Sui et al. Nanoscale
- Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors
- (2017) Yunching Chen et al. Scientific Reports
- In vitro and in vivo efficacy and safety evaluation of metapristone and mifepristone as cancer metastatic chemopreventive agents
- (2016) Jichuang Wang et al. BIOMEDICINE & PHARMACOTHERAPY
- Polyethylene glycol (PEG): a versatile polymer for pharmaceutical applications
- (2016) Anisha A. D’souza et al. Expert Opinion on Drug Delivery
- Sorafenib with ASC-J9®synergistically suppresses the HCC progressionviaaltering the pSTAT3-CCL2/Bcl2 signals
- (2016) Junjie Xu et al. INTERNATIONAL JOURNAL OF CANCER
- Improved antitumor activity of epirubicin-loaded CXCR4-targeted polymeric nanoparticles in liver cancers
- (2016) Sun Di-Wen et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- ABCC2 (1249G > A) polymorphism implicates altered transport activity for sorafenib
- (2016) Danyun Wei et al. XENOBIOTICA
- Pharmacoproteomic analysis reveals that metapristone (RU486 metabolite) intervenes E-cadherin and vimentin to realize cancer metastasis chemoprevention
- (2016) Suhong Yu et al. Scientific Reports
- Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity
- (2015) Hiroshi Maeda ADVANCED DRUG DELIVERY REVIEWS
- CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer
- (2015) Dong-Yu Gao et al. BIOMATERIALS
- Telodendrimer nanocarrier for co-delivery of paclitaxel and cisplatin: A synergistic combination nanotherapy for ovarian cancer treatment
- (2015) Liqiong Cai et al. BIOMATERIALS
- Global cancer statistics, 2012
- (2015) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma
- (2015) Jiang Chen et al. CANCER LETTERS
- Molecular Pathways: Targeting the CXCR4-CXCL12 Axis--Untapped Potential in the Tumor Microenvironment
- (2015) S. Scala CLINICAL CANCER RESEARCH
- CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice
- (2015) Yunching Chen et al. HEPATOLOGY
- PLGA nanoparticles prepared by nano-emulsion templating using low-energy methods as efficient nanocarriers for drug delivery across the blood–brain barrier
- (2015) C. Fornaguera et al. JOURNAL OF CONTROLLED RELEASE
- Delivery of siRNA Using CXCR4-targeted Nanoparticles Modulates Tumor Microenvironment and Achieves a Potent Antitumor Response in Liver Cancer
- (2015) Jia-Yu Liu et al. MOLECULAR THERAPY
- EZH2-mediated loss of miR-622 determines CXCR4 activation in hepatocellular carcinoma
- (2015) Haiou Liu et al. Nature Communications
- Synthesis, Spectral Characterization, and In Vitro Cellular Activities of Metapristone, a Potential Cancer Metastatic Chemopreventive Agent Derived from Mifepristone (RU486)
- (2014) Jichuang Wang et al. AAPS Journal
- Nanoparticles with Precise Ratiometric Co-Loading and Co-Delivery of Gemcitabine Monophosphate and Cisplatin for Treatment of Bladder Cancer
- (2014) Lei Miao et al. ADVANCED FUNCTIONAL MATERIALS
- Targeted delivery of doxorubicin to A549 lung cancer cells by CXCR4 antagonist conjugated PLGA nanoparticles
- (2014) Chuda Chittasupho et al. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
- Hepatocellular carcinoma: clinical frontiers and perspectives
- (2014) Jordi Bruix et al. GUT
- The Unique Pharmacological Characteristics of Mifepristone (RU486): From Terminating Pregnancy to Preventing Cancer Metastasis
- (2014) Jianzhong Chen et al. MEDICINAL RESEARCH REVIEWS
- Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma
- (2013) Yingjian Liang et al. HEPATOLOGY
- αB-crystallin complexes with 14-3-3ζ to induce epithelial-mesenchymal transition and resistance to sorafenib in hepatocellular carcinoma
- (2013) Xiao-Yong Huang et al. HEPATOLOGY
- Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice
- (2013) Yunching Chen et al. HEPATOLOGY
- Small Molecule Inhibitors of CXCR4
- (2013) Bikash Debnath et al. Theranostics
- Aptamer-functionalized PEG–PLGA nanoparticles for enhanced anti-glioma drug delivery
- (2011) Jianwei Guo et al. BIOMATERIALS
- Quantitative control of targeting effect of anticancer drugs formulated by ligand-conjugated nanoparticles of biodegradable copolymer blend
- (2011) Jing Zhao et al. BIOMATERIALS
- Activation of Phosphatidylinositol 3-Kinase/Akt Signaling Pathway Mediates Acquired Resistance to Sorafenib in Hepatocellular Carcinoma Cells
- (2011) K.-F. Chen et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
- (2010) T.-C. Chou CANCER RESEARCH
- A study of drug release from homogeneous PLGA microstructures
- (2010) Ghanashyam Acharya et al. JOURNAL OF CONTROLLED RELEASE
- Chemokine receptor CXCR4 expression in hepatocellular carcinoma patients increases the risk of bone metastases and poor survival
- (2009) Zuo-lin Xiang et al. BMC CANCER
- Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice
- (2009) B. Blanchet et al. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started